Jason Pitofsky, an officer of Regeneron Pharmaceuticals Inc, filed a Form 144 notice of proposed sale on November 4, 2026, covering 3,883 shares of common stock to be sold through UBS Financial Services Inc on NASDAQ:REGN.

Key Highlights

  • Proposed seller: Jason Pitofsky, identified in the filing as an officer of Regeneron Pharmaceuticals Inc.
  • Shares proposed for sale: 3,883 shares of common stock, with an aggregate market value of $3,789,808, according to the filing.
  • Approximate date of sale: November 4, 2026, through broker UBS Financial Services Inc, located at 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ 07086.
  • Source of shares: Three separate stock option grants acquired on December 9, 2020 (905 shares), December 8, 2021 (1,478 shares), and December 16, 2022 (1,500 shares), all from Regeneron Pharmaceutical Inc via cashless exercise.
  • Shares outstanding: The filing reports 101,630,713 shares of common stock outstanding.
  • Prior sales: The filing reports nothing to report for securities sold during the past 3 months.

Pitofsky's Proposed Rule 144 Sale: Stock Option Origins and Transaction Details

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Jason Pitofsky, an officer of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), proposes to sell 3,883 shares of Regeneron common stock. The aggregate market value of the proposed sale is listed as $3,789,808. The filing names UBS Financial Services Inc as the executing broker, with a listed address of 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ 07086.

The filing discloses that the shares to be sold originate from three distinct stock option grants. The first grant, dated December 9, 2020, covers 905 shares. The second grant, dated December 8, 2021, covers 1,478 shares. The third grant, dated December 16, 2022, covers 1,500 shares. All three grants were received from Regeneron Pharmaceutical Inc and are described in the filing as being settled through cashless exercise, with payment date of November 4, 2026 for each.

The filing notes no securities of Regeneron were sold by Pitofsky in the three months preceding the notice date. The form was signed by Joseph Cassidy, of UBS Financial Services Inc, as attorney-in-fact for Jason Pitofsky, and carries a notice date of November 4, 2026. Regeneron Pharmaceuticals Inc is listed with SEC File Number 000-19034, with principal offices at 777 Old Saw Mill Road, Tarrytown, New York 10591.

What Was Disclosed

Regeneron officer Jason Pitofsky filed a Form 144 on November 4, 2026, proposing to sell 3,883 shares of common stock with an aggregate market value of $3,789,808, sourced from three stock option grants dating to 2020, 2021, and 2022, all settled via cashless exercise.